Biotech | PressReach

Acasti Pharma Announces Annual Grants of Performance Stock Options

PressReach · Jun 22, 2022

Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis

PressReach · Jun 21, 2022

Acasti Pharma Reports Fiscal Year 2022 Operational Results

PressReach · Jun 21, 2022

Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

PressReach · Jun 17, 2022

ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

PressReach · Jun 17, 2022

Bionano Genomics Announces Participation at the European Association for Cancer Research (EACR) Congress 2022 Featuring OGM Applications for Cancer Research

PressReach · Jun 16, 2022

Acasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call

PressReach · Jun 16, 2022

Hoth Announces Adjournment of Annual Meeting of Shareholders Until June 23, 2022

PressReach · Jun 15, 2022

Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty

PressReach · Jun 14, 2022

Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

PressReach · Jun 14, 2022

Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting

PressReach · Jun 13, 2022

Bionano Genomics Announces Participation at the European Society of Human Genetics Conference (ESHG) 2022 Featuring OGM Across a Broad Range of Clinical Research Applications and a Collaborative Product Development with Hamilton

PressReach · Jun 10, 2022